Celyad SA is planning to sell 1.8 million ordinary shares in a global offering.
The Belgium-based biopharmaceutical company will offer ordinary shares in the form of American depositary shares, or ADSs, in the U.S., Canada and certain countries outside of Europe. Each ADS offered will represent the right to receive 1 ordinary share.
Concurrently, the company will offer ordinary shares in a private placement in Europe and certain countries outside of the U.S. and Canada.
Celyad intends to grant the underwriters an option to buy up to an additional 15% of the ordinary shares or ADSs proposed to be sold in the offering.
The closing of the global offering is subject to market and other conditions.
Wells Fargo Securities LLC and Bryan Garnier & Co. are acting as joint book-running managers, while Bank Degroof Petercam NV and LifeSci Capital LLC are acting as co-managers for the offering. Kempen & Co NV is Celyad's adviser for the offering.